- |||||||||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
Journal: Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome. (Pubmed Central) - May 23, 2024 Renal expression patterns and spatial distribution of several metabolites differ in AS compared to WT mice. While Lina and Empa treatments similarly partially slow the progression of kidney disease in AS, the metabolic mechanisms conferring the protective effect may be different.
- |||||||||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Clinical, Journal, Combination therapy: Evaluating the Efficacy, Safety, and Tolerability of Combination Therapy of Dapagliflozin and Linagliptin Over Dapagliflozin and Vildagliptin in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin. (Pubmed Central) - May 13, 2024 Conclusions Compared to dapagliflozin and vildagliptin combination therapy, dapagliflozin and linagliptin fixed-dose combination provided clinically significant improvements in glycemic control. Because of its effectiveness, safety, and tolerability, the fixed-dose combination of dapagliflozin and linagliptin was a better option for treating T2DM patients who had previously only received metformin monotherapy.
- |||||||||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Journal, IO biomarker: Linagliptin ameliorates tacrolimus-induced renal injury: role of Nrf2/HO-1 and HIF-1?/CTGF/PAI-1. (Pubmed Central) - May 5, 2024 Because of its effectiveness, safety, and tolerability, the fixed-dose combination of dapagliflozin and linagliptin was a better option for treating T2DM patients who had previously only received metformin monotherapy. Lina ameliorated TAC-induced kidney injury through modulation of oxidative stress, hypoxia, and apoptosis related proteins.
- |||||||||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
PK/PD data, Preclinical, Journal: Unveiling Pharmacokinetics and Drug Interaction of Linagliptin and Pioglitazone HCl in Rat Plasma Using LC-MS/MS. (Pubmed Central) - Apr 29, 2024 The linagliptin (LIN) and pioglitazone HCl (PIO) combination, currently undergoing phase III clinical trials for diabetes mellitus treatment, demonstrated significant improvements in glycemic control...Herein, a sensitive reverse-phase high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry method was developed for simultaneous determination of LIN and PIO in rat plasma using alogliptin as an internal standard...Molecular modeling revealed the significant interaction of LIN and PIO with P-glycoprotein. Therefore, the drug-drug interaction between LIN and PIO deserves further study to improve drug therapy and prevent dangerous adverse effects.
- |||||||||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Trial completion, Enrollment change, Trial completion date: Gliflozins and Cardiovascular Risk Factors in Type 2 Diabetes (GIOIA) (clinicaltrials.gov) - Apr 18, 2024 P=N/A, N=1150, Completed, GM is partially associated with these improvements since the SEM models suggest a weak association between specific bacterial genera and improvements in IS and P?f. Recruiting --> Completed | N=555 --> 1150 | Trial completion date: Dec 2025 --> Dec 2023
- |||||||||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Januvia (sitagliptin) / Merck (MSD)
Journal: Identification of Risk Factors for Gliptin-associated Bullous Pemphigoid among Diabetic Patients. (Pubmed Central) - Apr 9, 2024 These results suggest gliptins should be prescribed with caution to patients with type 2 diabetes with coexisting Alzheimer's and other dementias, or patients receiving long-term use of thiazides and loop diuretics. The use of sitagliptin over linagliptin and vildagliptin should be preferred in these patients.
- |||||||||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Linagliptin increases urinary sodium excretion via deactivating renal ENaC in diabetic rodents and patients with diabetes mellites (SUN-108; Exhibition Hall and Main Foyer) - Mar 8, 2024 - Abstract #ISNWCN2024ISN_WCN_1014; [1] SDT-fatty rats, an obese DM model, were given high salt diet and categorized into four groups as followings; Sham, DM-N, DM-N treated with Empagliflozin for 12 weeks (EMPA), DM-N treated with 6-week EMPA followed by 6-week treatment with linagliptin (EMPA + LINA). LINA can become a potent to prevent the progression of DM-N through deactivating ENaC leading to increased urinary sodium excretion.
- |||||||||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Review, Journal: Dietary gallic acid as an antioxidant: A review of its food industry applications, health benefits, bioavailability, nano-delivery systems, and drug interactions. (Pubmed Central) - Feb 28, 2024 GA may induce drug interactions with conventional drugs, such as hydroxyurea, linagliptin, and diltiazem, due to its inhibitory effects on metabolic enzymes, including cytochrome P450 3A4 and 2D6, and transporters, including P-glycoprotein, breast cancer resistance protein, and organic anion-transporting polypeptide 1B3. In conclusion, in-depth studies of GA on food industry applications, health benefits, bioavailability, nano-delivery systems, and drug interactions have laid the foundation for its comprehensive application as a food additive and dietary supplement.
- |||||||||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Salty, Sweet, and Severe: A Case of Linagliptin-induced Severe Hyponatremia (San Diego Convention Center, Room 1A-B (Upper Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_7689; The mechanism through which a DPP-4 inhibitor would induce hyponatremia remains unclear and warrants further attention. This case expands the literature by offering an additional medication to consider in the setting of acute severe hyponatremia to inform key management and workup decisions.
- |||||||||| Nesina (alogliptin) / Takeda, Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Rare Case of Life-threatening Angioedema Induced by DPP-4 Inhibitor (San Diego Convention Center, Area A (Hall A-B2, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_1612; 3 mg IM, Pepcid 40 mg IV, and Solu-Medrol 125 mg IV in the emergency room...Studies using the FDA Adverse Event reporting system identify that Angioedema with DPP4 inhibitors with the exception of Linagliptin (which provides more potent prolongation of bradykinin half-life) generally occurs with concomitant ACE inhibitor use...Enhancing clinicians' understanding and recognition of this adverse effect can expedite the diagnosis and treatment of DPP-4-associated angioedema as well as improve patient surveillance when concomitantly using ACEi. Transverse view of CT Neck with contrast demonstrating para epiglottic mucosal edema.
- |||||||||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, BMS-202 / Bayer
Journal: Hydrogel-mediated tumor T cell infiltration and immune evasion to reinforce cancer immunotherapy. (Pubmed Central) - Jan 30, 2024 Therefore, the hydrogel in combination with CXCL10 demonstrated powerful cancer immunotherapy against primary and distant tumors, along with efficient inhibition of lung metastasis. Our study not only offers a potent platform against tumors, but also provides a conceptually new approach to reinforce cancer immunotherapy.
- |||||||||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Journal, Combination therapy: Linagliptin in combination with insulin suppresses apoptotic unfolded protein response in ovaries exposed to type 1 diabetes. (Pubmed Central) - Dec 13, 2023 The use of linagliptin and insulin increased the expression of pro-survival XBP1s transmembrane protein and decreased the expression of proapoptotic ATF4, pJNK1/2, cleaved caspase 12, and cleaved caspase 3 in mouse ovaries. Our study provides new therapeutic evidence that linagliptin administered in addition to insulin induces ER stress mechanism-dependent survival in ovaries with type 1 diabetes.
- |||||||||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Journal: Gliptin-induced bullous pemphigoid. (Pubmed Central) - Nov 30, 2023 The proper management of autoimmune bullous skin disorders in elderly patients includes a scrupulous assessment of plausible drug triggers. Systemic corticosteroids for treating severe cases of DIBP can worsen concomitant diseases which often necessitates multidisciplinary care.
- |||||||||| Cotellic (cobimetinib) / Exelixis, Roche, tiragolumab (RG6058) / Roche, Tecentriq (atezolizumab) / Roche
Enrollment closed, Metastases: MORPHEUS-EC: A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) (clinicaltrials.gov) - Oct 27, 2023 P1/2, N=410, Active, not recruiting, The current paper reviews the collected data supporting the role of OSR9. Recruiting --> Active, not recruiting
- |||||||||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Journal: A Quantitative Systems Pharmacology Model of the Incretin Hormones GIP and GLP1, Glucagon, Glucose, Insulin, and the Small Molecule DPP-4 Inhibitor, Linagliptin. (Pubmed Central) - Sep 16, 2023 Since the glucose regulation modeling framework within the QSP model is "drug-independent", our model can be easily adopted by others to evaluate the effect of other DPP-4 inhibitors on glucose control system. In addition, our QSP model, which contains more components than other reported glucose regulation models, can potentially be used to evaluate the effect of combination antidiabetic therapy targeting different components of glucose control system.
- |||||||||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Journal: Simplifying Type 2 DM Care with Linagliptin: A Position Paper. (Pubmed Central) - Aug 31, 2023 In addition, our QSP model, which contains more components than other reported glucose regulation models, can potentially be used to evaluate the effect of combination antidiabetic therapy targeting different components of glucose control system. Linagliptin therapy is simplifying the management of T2DM with good efficacy and its use across a wide range of patients without any dose modification.
- |||||||||| Tremfya (guselkumab) / J&J
Hydroxyzin- induced Acute Generalized Exanthematous Pustulosis in psoriatic patient treated with Guselkumab (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_2351; We report a case of a 72-year old- male patient with type II diabetes mellitus, diabetic nephropathy and chronic kidney disease (CKD) that developed BP after linagliptin introduction into the antidiabetic therapy. It is evident from this report that gliptins might be related to bullosius pemphigoid.** Physicians should be aware of the possible reaction to** Dipeptidyl peptidase-4 (DPP4) inhibitors (gliptins) and always keep it in mind as a potential trigger factor for bullous pemphigoid.
- |||||||||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Tavalisse (fostamatinib) / Rigel, Kissei
Journal: A deep learning-based drug repurposing screening and validation for anti-SARS-CoV-2 compounds by targeting the cell entry mechanism. (Pubmed Central) - Aug 21, 2023 Using a SARS-CoV-2 pseudovirus system, we further identify several drug candidates including Fostamatinib, Linagliptin, Lysergol and Sophoridine that can effectively block the cell entry of SARS-CoV-2 variants into human lung cells even at a nanomolar scale. These efforts not only illuminate the feasibility of applying deep learning-based drug repositioning for antiviral agents by targeting a specified mechanism, but also provide a valuable resource of promising drug candidates or lead compounds to treat COVID-19.
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Observational data, Journal: Indicators of diabetes mellitus after liraglutide, sitagliptin/metformin, linagliptin, and sitagliptin (Pubmed Central) - Aug 8, 2023 Blood pressure control went from 64.5, 66.7, and 67 to 82.4, 85.1, and 83.1%. The control indicators in the unit improved, however, the patients who used the new keys did not show any difference.
|